Contract development and manufacturing (CDMO), complex hospital generics and consumer healthcare businesses, spun off from Piramal Enterprises.
Contract development and manufacturing (CDMO), complex hospital generics and consumer healthcare businesses, spun off from Piramal Enterprises.
Earns most from contract work for drugmakers, paid through development projects and longer manufacturing supply agreements, with plants in India, the UK and North America. Complex hospital generics, such as inhaled anaesthetics, are sold direct to hospitals, and the consumer brands through Indian retail. The Piramal family controls it, with Carlyle as a significant investor.
In one line: A diversified Indian CDMO plus consumer health arm.
Moat: narrow (regulatory licence, process know-how). Regulated manufacturing plants and long-term CDMO contracts create switching costs for pharma clients.
Headquarters: Mumbai, India · Founded: 2011 · Employees: 10,440
Size Piramal Pharma (PPLPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $3.40B, the 268th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹238.95 on 18 Nov 2026.
Performance Over six months the shares gained 37.9%, against +3.4% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 9.4% over the last twelve months (peer median +10.3%); the operating margin is 3.2% (peer median 12.7%).
Valuation It trades at 150.8× forward earnings against a peer median of 19.6× (most expensive of 14).
Capital Return on invested capital runs 14.1 points below its cost of capital (15.8% WACC).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹97.8B | ₹88.7B | ₹91.5B | ₹81.7B | ₹70.8B |
| Revenue growth | — | -3% | +12% | +15% | — |
| Gross profit | ₹27.1B | ₹15.4B | ₹19.6B | ₹16.8B | ₹11.0B |
| EBITDA | ₹12.0B | ₹10.00B | ₹15.2B | ₹12.6B | ₹6.41B |
| Net income | -₹2.09B | -₹3.26B | ₹911M | ₹178M | -₹1.86B |
| Free cash flow | n/a | ₹5.10B | -₹1.64B | -₹1.47B | -₹6.76B |
| Capital expenditure | n/a | ₹8.90B | ₹6.64B | ₹7.12B | ₹9.65B |
| Total debt | ₹58.7B | ₹56.7B | ₹48.6B | ₹47.1B | ₹56.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Piramal Pharma PPLPHARMA.NS | $3.40B | +38% | +9% | 3% | 150.8× | n/a |
| Syngene International SYNGENE.NS | $1.88B | -8% | -6% | 13% | 70.7× | 36.4% |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
| SAI Life Sciences SAILIFE.NS | $4.07B | +59% | +16% | 22% | 87.2× | n/a |
| Laurus Labs LAURUSLABS.NS | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% |
| Cohance Lifesciences COHANCE.NS | $1.87B | +7% | +14% | 2% | 96.3× | n/a |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| Siegfried SFZN.SW | $3.51B | -17% | +4% | 16% | 16.8× | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | $1.59B | -8% | +18% | 7% | 29.0× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PPLPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +22.9% | -1.8% | 3rd highest of 21 |
| 6-month return | +37.9% | +3.4% | 5th highest of 20 |
| Distance from 52-week high | -5.9% | -24.1% | 3rd highest of 21 |
| Revenue growth (TTM) | +9.4% | +10.3% | 9th lowest of 18 |
| Operating margin | 3.2% | 12.7% | 4th lowest of 17 |
| Forward P/E | 150.8× | 19.6× | most expensive of 14 |
| ROIC minus cost of capital | -14.1 pp | +4.3 pp | 2nd lowest of 16 |
| EV / EBITDA | 30.7× | 19.8× | 4th most expensive of 9 |
| Net debt / EBITDA | 4.2× | 0.8× | 2nd most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |